SEGMENT REPORTING

12 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE N - SEGMENT REPORTING

We are a medical device company serving the surgical product and cancer treatment markets, operating in two business segments. Our surgical products segment consists of wound closure, vascular access, and specialty needle products. Our brachytherapy seed business manufactures, performs custom loading, markets, and distributes “seeds” primarily in the minimally invasive treatment of localized prostate cancer.  Our brachytherapy product line includes our palladium-103 TheraSeed® device and our iodine-125 AgX100® device.

 The following tables provide certain information for these segments (in thousands):

	Year ended December 31,
	2012			2011			2010
Revenue
Surgical products	$	59,933		$	59,409		$	59,027
Brachytherapy seed		23,597			24,077			23,752
Intersegment eliminations		(971	)		(756	)		(595	)
	$	82,559		$	82,730		$	82,184
Earnings from operations
Surgical products	$	696		$	607		$	215
Brachytherapy seed		3,122			4,923			3,685
Intersegment eliminations		(51	)		(34	)		(14	)
	$	3,767		$	5,496		$	3,886
Capital expenditures
Surgical products	$	1,357		$	1,780		$	8,316
Brachytherapy seed		565			246			749
	$	1,922		$	2,026		$	9,065
Depreciation and amortization
Surgical products	$	4,917		$	4,536		$	4,686
Brachytherapy seed		2,975			2,689			2,521
	$	7,892		$	7,225		$	7,207

We evaluate business segment performance based on segment revenue and segment earnings from operations. Earnings from operations by segment do not include interest expense, interest income, other income and expense, or provisions for income taxes. Intersegment eliminations are for surgical products segment sales transactions. Corporate expenses are allocated based upon the relative revenue for each segment.

Segment information related to significant assets follows (in thousands):

	December 31,
	2012			2011
Identifiable assets
Surgical products	$	70,361		$	72,475
Brachytherapy seed		62,474			60,791
Corporate investment in subsidiaries		111,439			111,439
Intersegment eliminations		(138,549	)		(128,887	)
	$	105,725		$	115,818
Intangible assets
Surgical products	$	6,644		$	9,404
Brachytherapy seed		4,376			55
	$	11,020		$	9,459

Information regarding revenue by geographic regions follows (in thousands):

	Year ended December 31,
	2012		2011		2010
Product sales
United States	$	69,259	$	70,836	$	71,853
Europe		7,361		7,663		7,544
Other foreign countries		3,388		1,955		1,286
		80,008		80,454		80,683
License and fee income
United States		1,103		953		603
Canada		1,448		1,323		898
		2,551		2,276		1,501
	$	82,559	$	82,730	$	82,184

Foreign sales are attributed to countries based on location of the customer. The license fees attributed to Canada are with Nordion, a Canadian based company, for the license of our TheraSphere® product. Less than 10% of all foreign product sales are related to the brachytherapy segment. Substantially all of our long-lived assets are located within the United States.